These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22903665)

  • 1. Naturally occurring antibodies as therapeutics for neurologic disease: can human monoclonal IgMs replace the limited resource IVIG?
    Warrington AE; Van Keulen V; Pease LR; Rodriguez M
    Adv Exp Med Biol; 2012; 750():44-55. PubMed ID: 22903665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-mediated remyelination: relevance to multiple sclerosis.
    Bieber A; Asakura K; Warrington A; Kaveri SV; Rodriguez M
    Mult Scler; 2000 Oct; 6 Suppl 2():S1-5; discussion S33. PubMed ID: 11188771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Method of identifying natural antibodies for remyelination.
    Warrington AE; Rodriguez M
    J Clin Immunol; 2010 May; 30 Suppl 1(0 1):S50-5. PubMed ID: 20387101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remyelination-promoting human IgMs: developing a therapeutic reagent for demyelinating disease.
    Warrington AE; Rodriguez M
    Curr Top Microbiol Immunol; 2008; 318():213-39. PubMed ID: 18219820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis.
    Warrington AE; Asakura K; Bieber AJ; Ciric B; Van Keulen V; Kaveri SV; Kyle RA; Pease LR; Rodriguez M
    Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6820-5. PubMed ID: 10841576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel cross-reactive anti-idiotype antibodies with properties close to the human intravenous immunoglobulin (IVIg).
    Macias A; Arce S; Leon J; Mustelier G; Bombino G; Domarco A; Perez R; Lage A
    Hybridoma; 1999 Jun; 18(3):263-72. PubMed ID: 10475241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases.
    Wootla B; Watzlawik JO; Warrington AE; Wittenberg NJ; Denic A; Xu X; Jordan LR; Papke LM; Zoecklein LJ; Pierce ML; Oh SH; Kantarci OH; Rodriguez M
    JAMA Neurol; 2015 Nov; 72(11):1346-53. PubMed ID: 26389734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-faceted role of naturally occurring autoantibodies in fighting pathogens.
    Bouhlal H; Kaveri S
    Adv Exp Med Biol; 2012; 750():100-13. PubMed ID: 22903669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idiotypic interactions between normal human polyspecific IgG and natural IgM antibodies.
    Rossi F; Guilbert B; Tonnelle C; Ternynck T; Fumoux F; Avrameas S; Kazatchkine MD
    Eur J Immunol; 1990 Sep; 20(9):2089-94. PubMed ID: 2209705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naturally occurring autoantibodies against β-Amyloid.
    Bach JP; Dodel R
    Adv Exp Med Biol; 2012; 750():91-9. PubMed ID: 22903668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human monoclonal IgM antibody promotes CNS myelin repair independent of Fc function.
    Ciric B; Howe CL; Paz Soldan M; Warrington AE; Bieber AJ; Van Keulen V; Rodriguez M; Pease LR
    Brain Pathol; 2003 Oct; 13(4):608-16. PubMed ID: 14655764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire.
    Watzlawik JO; Wootla B; Painter MM; Warrington AE; Rodriguez M
    Expert Rev Neurother; 2013 Sep; 13(9):1017-29. PubMed ID: 24053345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide.
    Paul S; Planque S; Nishiyama Y
    J Clin Immunol; 2010 May; 30 Suppl 1(Suppl 1):S43-9. PubMed ID: 20454852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-HLA-E monoclonal antibodies reacting with HLA-la and lb alleles like IVIg as potential IVIg-immunomimetics: an evolving therapeutic concept.
    Ravindranath MH; Zhu D; Pham T; Jucaud V; Hopfield J; Kawakita S; Terasaki PI
    Clin Transpl; 2013; ():293-305. PubMed ID: 25095521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A unique population of circulating autoantibodies promotes central nervous system remyelination.
    Asakura K; Rodriguez M
    Mult Scler; 1998 Jun; 4(3):217-21. PubMed ID: 9762677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrolysis of myelin basic protein by IgM and IgA antibodies from the sera of patients with multiple sclerosis.
    Polosukhina DI; Buneva VN; Doronin BM; Tyshkevich OB; Boiko AN; Gusev EI; Favorova OO; Nevinsky GA
    Med Sci Monit; 2005 Aug; 11(8):BR266-72. PubMed ID: 16049372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease.
    Mitsunaga Y; Ciric B; Van Keulen V; Warrington AE; Paz Soldan M; Bieber AJ; Rodriguez M; Pease LR
    FASEB J; 2002 Aug; 16(10):1325-7. PubMed ID: 12154009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promotion of remyelination by immunoglobulins: implications for the treatment of multiple sclerosis.
    Trebst C; Stangel M
    Curr Pharm Des; 2006; 12(2):241-9. PubMed ID: 16454740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg).
    Vassilev T; Gelin C; Kaveri SV; Zilber MT; Boumsell L; Kazatchkine MD
    Clin Exp Immunol; 1993 Jun; 92(3):369-72. PubMed ID: 7685668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of intravenous immunoglobulins for naturally occurring autoantibodies against amyloid-beta.
    Balakrishnan K; Andrei-Selmer LC; Selmer T; Bacher M; Dodel R
    J Alzheimers Dis; 2010; 20(1):135-43. PubMed ID: 20164596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.